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Inducing Chronic Excitotoxicity in the
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Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia
We report the methodology for the chronic delivery of an excitotoxin to the mouse
spinal cord via surgically implanted osmotic mini-pumps. Previous studies have
investigated the effect of chronic application of excitotoxins in the rat, however
there has been little translation of this model to the mouse. Using mice that
express yellow ﬂuorescent protein (YFP), motor neuron and neuromuscular junction
alterations can be investigate following targeted, long-term (28 days) exposure to
the α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor excitotoxin,
kainic acid. By targeting the L3-4 region of the lumbar spinal cord, with insertion of
an intrathecal catheter into the subarachnoid space at L5, chronic application of the
kainic acid results in slow excitotoxic death in the anterior ventral horn, with a signiﬁcant
(P < 0.05) reduction in the number of SMI-32 immunopositive neurons present after
28 days infusion. Use of the Thy1-YFP mice provides unrivaled visualization of the
neuromuscular junction and enables the resultant distal degeneration in skeletal muscle
to be observed. Both neuromuscular junction retraction at the gastrocnemiusmuscle and
axonal fragmentation in the sciatic nerve were observed after chronic infusion of kainic
acid for 28 days. Lower motor neuron, and distal neuromuscular junction, degeneration
are pathological hallmarks of the devastating neurodegenerative disease Amyotrophic
Lateral Sclerosis (ALS). This mouse model will be advantageous for increasing our
understanding of how the pathophysiological phenomena associated with this disease
can lead to lower motor neuron loss and distal pathology, as well as providing a robust
in vivo platform to test therapeutic interventions directed at excitotoxic mechanisms.
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INTRODUCTION
Excitotoxicity is a common pathogenic mechanism in many neurodegenerative diseases and may
play an important initiating role in amyotrophic lateral sclerosis (ALS) (Vucic and Kiernan, 2009;
Mehta et al., 2013). ALS is the most common form of motor neuron disease and one of the
most devastating neurodegenerative disorders (Talbot, 2014), with patients dying within 2–5 years
of diagnosis from respiratory failure. Gene mutations affecting several proteins, including TDP-
43, FUS, c9orf72, and SOD1 have been identified in familial forms of the disease, however, the
majority of cases appear sporadic (Kiernan et al., 2011; Ajroud-Driss and Siddique, 2015). ALS
results in muscle paralysis caused by the degeneration of the motor neurons and neuromuscular
junctions in the cortico-motor-neuronal system, however it is not clear why these neurons are
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selectively vulnerable. Although it is likely that ALS is a
multifactorial disease, potentially involving RNA dysfunction,
protein misfolding and aggregation, autophagy, ER stress and
axonal disruption (Gibson and Bromberg, 2012), there is
increasing evidence for a pivotal role for excitotoxicity in the
pathogenesis, with a significant period of neuronal dysfunction
occurring prior to frank cell loss (Corona et al., 2007; Kiernan
et al., 2011). Indeed, hyperexcitability of both upper and lower
motor neurons has been reported prior to the onset of motor
symptoms(Pieri et al., 2003; Vucic and Kiernan, 2006; van
Zundert et al., 2008; Menon et al., 2015) and the only current
treatment available for ALS, riluzole, involves inhibition of this
excitotoxic pathway (Miller et al., 2012).
Previous research has demonstrated that motor neurons
are selectively vulnerable to α-amino-3-hydroxy-5-methyl-
4-isoxazolepropionic acid (AMPA) mediated excitotoxicity
(Vandenberghe et al., 2000; King et al., 2007). To explore this
AMPA mediated mechanism of neurodegeneration, a rat model
of site-specific application of excitotoxins to the spinal cord was
developed (Nakamura et al., 1994; Kwak and Nakamura, 1995;
Hirata et al., 1997; Sun et al., 2006). Thismodel demonstrated that
exposing the spinal cord to an excitotoxin, specifically an AMPA
agonist, leads to significant motor neuron loss and replicates the
loss of motor function that is characteristic of the human disease
(Nakamura et al., 1994; Kwak and Nakamura, 1995; Hirata et al.,
1997; Sun et al., 2006). These previous studies were restricted to
analysis of neuropathology in the spinal cord and resulting motor
dysfunction. Despite the continued implication of excitotoxicity
in the pathobiology of ALS, the use of this model has been
limited.
Here, we report the methodology required to achieve chronic
exposure of the mouse lumbar region of the spinal cord to
kainic acid, over a 28 day time course, and the resulting
localized excitotoxic death of motor neurons. By modifying
both the region of the spinal cord targeted, and the entry
point of the delivery catheter, chronic application of toxins
can be achieved without causing physical damage to the
spinal cord. The application of this protocol to the Thy1-YFP
mouse, first described by Feng and colleagues (Feng et al.,
2000), extends the utility of this model. Yellow fluorescent
protein (YFP) mice express YFP ubiquitously in all lower
motor neuron axons and presynaptic terminals. Therefore, by
establishing a chronic model of slow excitotoxic motor neuron
death in the YFP mouse the distal axonal and neuromuscular
junction pathology can now be investigated in conjunction
with assessments of proximal cell body pathology and motor
neuron subtype vulnerability. With the ability to investigate
complete neuromuscular junction integrity and track their
changes over time we have previously used this model to
demonstrate that lower motor neurons have an underappreciated
capacity for plasticity prior to neuronal degeneration (Blizzard
et al., 2015). This model can be utilized to both increase our
understanding of the mechanisms that lead to the motor neuron
loss and neuromuscular junction degeneration that characterizes
neurodegenerative conditions such as ALS and also as a platform
for testing new therapeutic interventions targeted at lower motor
neurons.
MATERIALS AND METHODS
All experiments were approved by the Animal Ethics Committee
of the University of Tasmania and are in accordance with the
NHMRC Australian Code of Practice for the Care and Use of
Animals for Scientific Purposes, 2013. Thy-1 YFP mice (Jackson
Laboratory B6;CBA-Tg(Thy1-YFP)GJrs/GfngJ) were housed in
standard conditions (20◦C, 12/12 h light/dark cycle), with access
to food and water ad libitum. Animals were monitored daily for
signs of illness and stress and twice daily following surgery.
Osmotic Mini-Pump Preparation
Mini-pumps were prepared according to the protocol described
in Sun and collegues with modifications (Sun et al., 2006).
Pump preparation was performed in a sterile biohazard hood
using aseptic techniques. To ensure appropriate placement of
the catheter and focused delivery, the fluorescent anterograde
tracer Fluoro-Ruby (Fluorochrome, LLC) was added to both
vehicle control and excitotoxin solutions. Azlet R© model 1004
mini-pumps (infusion rate of 0.11 µL per hour) were filled with
5 mM kainic acid (Sigma) and 0.01 µM Fluoro-Ruby in artificial
cerebrospinal fluid (aCSF: 125 mM NaCl, 5 mM KCl, 10 mM
D-glucose, 10 mM HEPES, 2 mM CaCl2, 2 mM MgSO4 pH
7.4; all from Sigma). At this infusion rate the pumps release
2.5 µg of kainic acid per 24 h, which is 200-fold less than that
delivered systemically for seizure induction (Bouilleret et al.,
1999; Schauwecker, 2012; Iyengar et al., 2015). Vehicle control
pumps were loaded with 0.01µMFluoro-Ruby and an equal total
volume of aCSF. Polyurethane intrathecal catheters (0.23 mm
outside diameter × 0.09 inside diameter, Alzet R©) were removed
from their sterile packaging and two lines 3 mm apart were
marked on the distal end with a surgical skinmarker pen (Secure-
lineTM), to assist with later surgical placement of the catheter,
and the Teflon coated stylet wire removed. Catheters were loaded
with the kainic acid or vehicle control solution and attached to
the mini-pumps, being careful to ensure there were no bubbles
in the catheter. Pumps, with catheters attached, were then placed
into 50 mL centrifuge tubes (Sigma) and tubes filled with 0.9%
sterile saline, pH 7.4 and placed into a 37◦C incubator for 48 h to
ensure the pump was equilibrated and had started pumping.
Surgery Preparation
All surgical procedures were performed in a bioBUBBLE (Fort
Collins co.) with 80–100 HEPA filtered air circulations per hour,
designated for surgical procedures. Mice were transferred to
the room, acclimatized for 30 min and weighed. The surgical
bench and microscopes were wiped down with isopropanol
alcohol (Isowipe R©, Kimberly-Clark) and the area covered with
autoclaved surgical drapes. Surgical instruments were also
autoclaved. The osmotic pumps were transferred to a pre-
warmed heat pad at 37◦C. Mice were injected with a mixture of
ketamine (120 mg/kg)/xylazine (10 mg/kg) and left in their cage
on a heat pad until completely anesthetized (withdrawal reflexes
checked using toe pinch). Once anesthetized, the mouse was
removed from the cage, placed onto a heat pad, a small amount
of ophthalmic ointment (Refresh R© Lacri-lube R©) was placed on
each eyeball and the thoracolumbar area of the back, where the
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incision was to be made, was shaved and prepared for aseptic
surgery.
Osmotic Mini-Pump Insertion
To achieve targeted delivery of excitotixin to the L3-4 lumbar
region of the spinal cord the posterior portion of T13 vertebral
spine (Figure 1A) was removed and catheter inserted 3 mm
into the spinal column. A midline longitudinal incision in the
mid-lumbar area was made with a size 10-scalpel blade. A
subcutaneous pocket approximately 1.5 cm was blunt dissected
along the spine to create an area for the pump to be
placed (Figures 1B,C). Using forceps and micro scissors (Fine
Science Tools), the posterior portion of the T13 vertebral spine
(Figures 1D,E) was removed. Using a diamond edged goniotomy
knife (Kaisers) the dura was gently pierced, being careful not to
puncture the central blood vessel. Using fine tipped 45◦ angled
forceps (Fine Science Tools) the pump catheter (which was cut at
the first 3 mm mark from the distal tip) was inserted anteriorly
into the subarachnoid space until the second 3 mm line is sitting
in line with the partially removed vertebrae. The pump was
gently squeezed with forceps, to check for resistance that would
indicate blockage of the catheter. A 29-gauge needle was filled
with VetbondTM (3MTM) and a drop carefully placed on top of
the catheter and surrounding muscle tissue (Figure 1G). Once
the glue had set, the pump was inserted in the subcutaneous
pocket along the spine (Figures 1F,G). The incision site was
closed with single interrupted sutures. A subcutaneous injection
of Temegesic (0.01 mg/kg) was administered in 1 mL of pre-
warmed saline. The mouse was then placed back in its home cage
and the cage placed on a head pad until the mouse was fully alert.
Subcutaneous Temegesic (0.01mg/kg) was administered every 12
h for the first 48 h following surgery.
Tissue Processing
Mice were terminally anaesthetized (pentobarbitone sodium, 140
mg/kg) and perfused with 4% paraformaldehyde (Sigma) up to 28
days infusion. Spinal columns and gastrocnemius muscles were
then dissected and left overnight in 4% paraformaldehyde. The
L1 to L5 region of the spinal column was dissected and placed
into a decalcification solution (5% nitric acid, 0.05% urea, both
from Sigma, in MilliQ R©) overnight. The spinal columns were
then washed with 0.1M phosphate buffered saline, pH 7.4 (PBS),
and placed into a series of overnight sucrose solutions (4, 18, and
30%, Sigma) in 0.1M PBS, 0.2% Sodium Azide (Sigma). Spinal
cord sections (30 µm) were serially cut on a cryostat at −17◦C
and mounted onto superfrostTM plus slides (Thermo Scientific).
For histology to investigate catheter placement (Figures 2A,B),
L3-6 blocks were sectioned longitudinally in 40 µm sections
and stained with Haemotoxylin and Eosin (H&E, Sigma). For
immunohistochemistry spinal cord and sciatic nerve slides were
incubated with primary antibodies (Anti-rat GFP IgG2a, 1:1000,
Nacalai Tesque, Anti-mouse SMI-32 IgG, 1:2000, Covance) in
0.3% Triton-X (Sigma) in 0.1M PBS overnight, washed in 0.1M
PBS and then incubated in secondary antibodies (All from Alexa-
Flour R©, 1:1000) for 90 min. SMI-32 is immunoreactive for
non-phosphorylated neurofilaments, enriched in alpha motor
neurons of the spinal ventral horn (Tsang et al., 2000). The
FIGURE 1 | (A) Schematic of the spinal cord, referenced from MRI images of
mouse C57BL/6J mouse (Harrison et al., 2013). (B) Schematic of the ﬁrst
procedure in the surgery—blunt dissection of skin pocket (arrowheads). (C)
Step 1: a skin incision is made over the lumber region of the spinal cord and
an anterior “pocket” is made under the skin for later placement of the pump.
Arrowhead denotes T13. (D) Schematic of the second procedure in the
surgery—vertebral spine dissection (arrowhead). (E) Step 2: the vertebral
spine T13 is partially removed with micro-dissecting scissors. (F) Schematic of
the third procedure in the surgery—catheter placement and pump insertion.
(G) Step 3: The catheter is placed inside the subarachnoid cavity, the incision
site secured with vetbond, and the pump placed in the skin pocket.
GFP antibody is immunoreactive for green fluorescent proteins
(GFP) and YFPs. Slides were then washed in 0.1M PBS, dried
and coverslipped with a fluorescent mounting medium (DAKO).
Gastrocnemius muscles were dissected, placed into a series of
overnight sucrose solutions (4, 18, and 30%, Sigma) in 0.1M
PBS for cryo-protection and sectioned at 80 µm. Muscle sections
were stained with α-bungarotoxin (1:100; Molecular Probes R©)
in 0.1M PBS. Sciatic nerves were dissected placed into a series
of overnight sucrose solutions (4, 18, and 30%, Sigma) in 0.1M
PBS for cryo-protection and sectioned at 10 µm. All images
were captured on a Zeiss LSM 510 confocal microscope using
Zen software. Z-stacks were flattened using ImageJ (NIH) and
processed in ImageJ and Photoshop (Adobe).
Statistical Analysis
The number of SMI-32 immunopositive neurons, with cell bodies
greater than 20 µm in diameter, present in the anterior ventral
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FIGURE 2 | (A) H&E stained spinal column section at T13, superior to L5
where the catheter is inserted. Arrowhead indicates the incision at T13 and
partial removel of veterbra. (B) L3-5 spinal cord section of the YFP mouse at 7
days infusion. Arrowhead indicates intact dorsal roots within the incision site.
(C) Longitudinal section of L1-5 of the spinal cord (YFP, green) showing the
location of Fluoro-Ruby (red) after 7 days infusion. (D) YFP (green) neurons in
the L4 spinal cord at 7 days infusion (E). Fluoro-Ruby (red) in the L4 spinal
cord at 7 days infusion F. Merged image of L4 spinal cord YFP (green) and
Fluoro-Ruby (red) at 7 days infusion. Arrowhead indicates a neuron in the
anterior ventral horn that is positive for YFP (D,F) and Fluoro-Ruby (E,F). Scale
bar—(A,B) −3 mm, (C) −600 µm (D–F) 150 µm.
horn in every second spinal cord section from L3 to L4 were
counted (n = 4 for both vehicle control and 5 mM kainic acid
animals). The number of intact and degenerating axons in the
gastrocnemius muscle was determined by the colocalization of
presynaptic YFP and post-synaptic α-bungarotoxin (intact) vs.
the absence of the presynaptic YFP (degenerating). Student’s t-
tests were performed in GraphPad Prism Software, with p < 0.05
considered significant.
RESULTS
Chronic Delivery to the Lumbar Region of
the Mouse Spinal Cord Can Be Achieved
by an Osmotic Mini-Pump and Intrathecal
Catheter
Histological staining (H&E) of the mouse spinal column 1-
day post-surgery demonstrated that using the described surgical
approach resulted in a discreet laminectomy at T13 (Figures 1A,
2A), which left the dorsal roots close to the entry point of the
catheter intact (Figure 2B). Fluoro-Ruby labeling was present
throughout the subarachnoid space of the lumber region of
the YFP spinal cord (Figure 2C). Furthermore, Fluoro-Ruby
labeling was present in the anterior ventral horn (Figures 2D–F,
arrowheads) confirming that the insertion of the catheter in
FIGURE 3 | (A,B) Neurons within the anterior ventral horn of the L3-4 region of
the spinal cord after 28 days infusion of vehicle control were immunoreactive
for SMI-32 (A red) and YFP (B green). (C) Merged image. (D,E) Neurons within
the anterior ventral horn of the L4 region of the spinal cord after 28 days
infusion of 5 mM kainic acid had a shrunken morphology and decreased
immunoreactivity for SMI-32 (D red) and YFP (E green). (F) Merged image. (G)
Quantiﬁcation of the number of SMI-32 positive neurons in the anterior ventral
horn demonstrated a signiﬁcant (P < 0.05) decrease after 28 days infusion of
kainic acid in comparison to vehicle control. Scale bar −100 µm. *P < 0.05.
the dorsal subarachnoid space leads to a dispersion of the fluid
around the spinal column that reaches the ventral spinal cord and
is taken up by neurons in this ventral region.
Chronic Kainic Acid Infusion to the L3-4
Region of the Mouse Spinal Cord Causes
Motor Neuron Loss
Immunohistochemistry directed at endogenous YFP and
SMI-32 demonstrated a loss of immunoreactivity in the
anterior ventral horns after 28 days infusion with 5 mM
kainic acid (Figures 3D–F), in comparison to vehicle
control (Figures 3A–C). Quantitation of the number of
cells immunopositive for SMI-32 demonstrated a significant
(P < 0.05) decrease in the anterior ventral horn after 28 days
infusion with 5 mM kainic acid in comparison to vehicle treated
controls (Figure 3G).
Chronic Kainic Acid Infusion to the L3-4
Region of the Mouse Spinal Cord Causes
Neuromuscular Junction Degeneration and
Axonal Pathology
In the current model the gastrocnemius muscle was used
to investigate neuromuscular junction pathology. Confocal
microscopy stacks of neuromuscular junctions after 28 days
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infusion with vehicle control showed intact neuromuscular
junction trees (Figure 4A) with complete colocalization between
the pre-synaptic YFP and the post-synaptic stain α-bungarotoxin
(Figure 4A inset). Following 28 days infusion of kainic acid (5
mM) the neuromuscular junction trees were frequently shrunken
(Figure 4B). Staining with α-bungarotoxin revealed that whilst
the post-synaptic terminal remains after 28 days infusion kainic
acid (5 mM) the pre-synaptic YFP positive terminal had retracted
(Figure 4B inset). Quantitation of the number of intact and
degenerating synapses demonstrated a significant (P < 0.05)
reduction in the percentage of intact synapses and a significant
(P < 0.05) increase in the percentage of degenerating synapses
in the 5 mM KA treated gastrocnemius muscles in comparison
the vehicle control (Figure 4C). Investigations in the sciatic nerve
demonstrated that after 28 days infusion axonal fragmentation
of YFP positive axons could be observed in the kainic acid
treated mice (Figures 5D,F) in comparison to vehicle control
treated animals (Figures 5A,C). Immunohisotchemistry for the
antibody directed at non-phosphorylated neurofilament, SMI-
32, indicated that the YFP loss and fragmentation of axons
in the KA treated sciatic nerve corresponded with a reduction
in immunoreactivity for SMI-32 (Figures 5D–E). Furthermore,
within the fragments of the degenerating axons, accumulations
of SMI-32 were sporadically present (Figure 5F arrowhead).
DISCUSSION
Herein we describe the methods required to model excitotoxin
mediated lower motor neuron death, and axonal and
neuromuscular junction degeneration in the spinal cord,
sciatic nerve and gastrocnemius muscle in the mouse. We
demonstrated that, with the use of osmotic mini-pumps and
intrathecal catheter attachments, the lumbar region of the mouse
spinal cord can be specifically targeted without causing overt
physical damage to surrounding areas. Furthermore, with the
use of the YFP expressing transgenic mouse we demonstrate
that chronic exposure of lower motor neuron cell bodies to
the AMPA receptor agonist kainic acid leads to axonal and
neuromuscular junction degeneration. This timely model will
be of use to investigate lower motor neuron pathology related
to neurodegenerative disease such as ALS. Indeed, ALS is
characterized by the loss of both upper and lower motor neurons
and the degeneration of the neuromuscular junction that is
replicated in this model.
The current method allows investigation of the effect of kainic
acid at the L3-4 region of the mouse spinal cord. The L3-4 region
of the spinal cord was selected as the site for kainic acid delivery
as in the mouse this is where the majority of the motor neurons
innervating the gastrocnemius muscle reside (Mohan et al.,
2014). Kainic acid is routinely used as an experimental AMPA
receptor agonist (Kwak and Nakamura, 1995; Nottingham and
Springer, 2003; Mazzone et al., 2010; Mitra et al., 2013). Previous
studies in the rat have demonstrated that delivery of AMPA
receptor agonists causes the death of motor neurons in the
spinal cord in a strain dependent manner (Sun et al., 2006).
Specifically there was a significant loss in the number of motor
FIGURE 4 | (A) After 28 days infusion with vehicle control, neuromuscular
junctions, labeled for YFP (green) and α-bungarotoxin (red), were intact and
showed classic morphologies (inset) throughout the gastrocnemius muscle.
(B) After 28 days infusion with 5 mM kainic acid the neuromuscular junctions
labeled for YFP (green) and α-bungarotoxin (red) were shrunken and the
pre-synaptic terminal appeared retracted, leaving only α-bungarotoxin (red)
intact (inset). (C) Quantitation of percentage of intact and degenerating
synapses in the gastrocnemius muscle in vehicle control and 5 mM Kainic acid
(KA) treated mice at 28 DPS demonstrated a signiﬁcant (*P < 0.05) reduction
in intact synapses and signiﬁcant (*P < 0.05) increase in degenerating
synapses. Scale bar—(A,B) –100 µm, (A,B insets) –50 µm.
neurons in the L5 spinal cord by 4 weeks in the Fischer rats
however this loss was not present until 8 weeks in theWistar rats.
Additionally they found that the neuron loss corresponded with
reduced rotarod performance. In the current mouse model, we
found a significant loss of SMI-32 immunopositive neurons in the
anterior ventral horn by 4 weeks (28 days infusion). Furthermore,
previous investigations in our laboratory have demonstrated that
this motor neuron loss also corresponds to significant hind limb
functional deficits (Blizzard et al., 2015). Collectively our data
demonstrate that AMPA mediated lower motor neuron death
is recapitulated in the mouse model. Our data, showing an
approximately 50% loss of large cells in the anterior ventral horn,
in conjunction with previous research indicating no significant
difference in cell loss at 28 days infusion between increasing
doses of kainic acid (5–10 mM kainic acid) (Blizzard et al., 2015)
suggests that there not all motor neurons in the anterior ventral
horn of the mouse are vulnerable to excitotoxic damage, in the
time frame investigated. Indeed, studies comparing populations
of neurons that are vulnerable and resistant in ALS indicate
that the susceptibility to ionotropic receptor alterations may
confer neuronal survival in this disease (Brockington et al.,
2013). Hence the current model of slow chronic excitotoxic
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FIGURE 5 | (A–C) Sciatic nerve section from vehicle control stained with YFP (A green) and SMI-32 (B red) at 28 days infusion demonstrated intact axons positive for
both YFP and SMI-32 (C). (D) Sciatic nerve section stained with YFP (D green) and SMI-32 (E red) after 28 days infusion of 5 mM kainic acid demonstrated a loss of
immunoreactivity of SMI-32 with sporadic accumulations of SMI-32 in fragmented YFP+ axons (F, arrowheads). Scale bar –100 µm.
death may not only be useful in investigating the neurons that
are vulnerable to excitotoxicity but also for determining the
morphological and biochemical characteristics that render motor
neuron subpopulations resistant.
The current model demonstrates that chronic lower motor
neuron excitotoxicity directly causes distal axonal pathology and
retraction of the pre-synaptic terminals of the neuromuscular
junction. Distal axonal alterations in lower motor neurons are
an early pathological mechanism occurring both in human
ALS (Fischer et al., 2004) and mouse models of motor neuron
diseases (Gillingwater and Ribchester, 2003; Moloney et al.,
2014). A common pathogenic consequence of ALS is disruption
to the axonal cytoskeleton, specifically the neurofilaments (Van
Damme et al., 2005). Interestingly, chronic excitotoxic spinal
cord infusion leads to a disruption in the phosphorylation
dependent neurofilament heavy chain marker SMI-32 distally,
in the sciatic nerve. Understanding how a proximal signal can
lead to distal pathology is vital in understanding the pathogenesis
of ALS as there is a desperate need to slow down or stop the
characteristic progressive neurodegeneration. Furthermore, the
gastrocnemius muscle is the largest muscle in the hind limb
of the mouse and is a mixed fiber type muscle (Bloemberg
and Quadrilatero, 2012) enabling the potential for not only
neuromuscular junction degeneration to be investigated but also
motor neuron firing type vulnerability.
Transgenic mice expressing YFP, first described in Feng et al.
(2000) have proved to be a valuable tool when modeling disease,
specifically when investigating axon degeneration. Previous
studies have used these mice to study axonal degeneration in
many models, including experimentally induced autoimmune
encephalomyelitis (Bannerman et al., 2005; Bannerman and
Hahn, 2007); ischemic injury in cortical slices (McCarran and
Goldberg, 2007), retinal ganglion cells following kainic acid
injection (Massoll et al., 2013), optic nerve crush (Lindsey et al.,
2015), and peripheral nerve injury (Groves et al., 2005). Herein,
we describe a method for inducing lower motor neuron axonal
degeneration chronically with an excitotoxin over a 28 days
time course in the spinal cord in vivo, this chronic evolution of
pathology being relevant to a range of neurodegenerative diseases
that manifest in the aging nervous system. Furthermore, due to
the design of the insertion these methods could also be applied
to the site-specific infusion of therapeutics, viral DNA constructs
and or anterograde and retrograde tracers.
This model recapitulates the characteristic pathology
associated with excitotoxic damage to the spinal cord in rats
and affords distinct advantages over previous models. Use of
the mouse has demonstrated that motor neuron subpopulations
are differentially vulnerable to chronic excitotoxicity. Use of the
YFP mouse allows the investigation into the mechanisms of
how chronic excitotoxicity leads to axonal and neuromuscular
junction pathology. Finally, establishment of a model that
recapitulates the sporadic form of ALS will be beneficial for the
discovery of therapeutic interventions that are not reliant upon
the currently identified genetic mutations.
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